Overview of the Recent Transaction State Street Corp, a prominent investment firm, recently expanded its portfolio by ...

Proleukin is a native IL-2 drug approved by the US Food and Drug Administration for the treatment of metastatic renal cell carcinoma and metastatic melanoma. Unfortunately, only a minority of ...

H.C. Wainwright 开始对 Mural Oncology (NASDAQ: MURA) 进行覆盖，给予该股票"买入"评级，目标价为$18.00。 该公司的乐观情绪源于 Mural Oncology 的 nemvaleukin alfa 的潜力，这是一种经过工程改造的白细胞介素-2 (IL-2) 细胞因子，旨在增强高剂量重组人 IL-2 的治疗效果，同时减少其有害副作用。 Mural O ...

UK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up to $210 million. Clinigen already bought ex-US rights to Proleukin (aldesleukin ...

it is worth noting that a substantial proportion of these are products already approved for other indications (e.g., Proleukin, Actimmune, Avonex, Intron A, Leukine, Neumega, Rebif, Betaseron ...

In this article, we will look at the 8 Most Promising Stocks to Buy According to Wall Street Analysts. Let’s look at where ...

We recently compiled a list of 13 Best Growth Stocks Under $10 to Buy. In this article we will look at where Iovance ...

With that said, here are the 13 Best Growth Stocks Under $10 to Buy.

Iovance had a strong Q2 with $31.1M in product revenue from Amtagvi and Proleukin. In addition, the company's net losses came in at $97.1M, down from $106.5M year-over-year. Moreover, their ...

The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or ...

A recombinant form of IL-2 has been used as a therapeutic for melanoma and renal cell carcinoma (RCC) for many years under the Proleukin (aldesleukin) trade name, originally by Novartis and ...